Topical MTII Suppresses Melanoma by Boosting PTEN and Inhibiting COX-2

Melanoma is an aggressive form of skin cancer with high metastatic potential, and current systemic treatments often come with significant side effects. Understanding the molecular pathways involved in its progression, such as the tumor suppressor PTEN and the pro-inflammatory enzyme COX-2 (cyclooxygenase II), is crucial for developing targeted therapies. This study investigates whether topical application of MTII (Melanotan II) can suppress melanoma growth by modulating these specific molecular targets.

Topical MTII therapy demonstrated a significant inhibitory effect on melanoma tumor growth. Tumor volume in the MTII-treated group was reduced by an impressive 68% compared to the vehicle control group (p<0.001). This substantial reduction was accompanied by significant molecular changes within the tumor tissue. The study found a 2.7-fold increase in PTEN (phosphatase and tensin homolog) protein expression, a known tumor suppressor, in the MTII-treated tumors (p<0.005). Concurrently, COX-2 (cyclooxygenase II) expression, an enzyme often overexpressed in cancers and linked to inflammation and proliferation, was decreased by 52% in the treated tumors (p<0.001). These findings strongly suggest that MTII exerts its anti-melanoma effects through a dual mechanism involving the upregulation of PTEN and the inhibition of COX-2.